Nothing Special   »   [go: up one dir, main page]

AU1225088A - Peptides having immunological properties 2-hiv-2 - Google Patents

Peptides having immunological properties 2-hiv-2

Info

Publication number
AU1225088A
AU1225088A AU12250/88A AU1225088A AU1225088A AU 1225088 A AU1225088 A AU 1225088A AU 12250/88 A AU12250/88 A AU 12250/88A AU 1225088 A AU1225088 A AU 1225088A AU 1225088 A AU1225088 A AU 1225088A
Authority
AU
Australia
Prior art keywords
hiv
peptides
immunological properties
peptidic
siv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU12250/88A
Other versions
AU608294B2 (en
Inventor
Marc Alizon
Lisa Chakrabarti
Francois Clavel
Ronald Desrosiers
Denise Guetard
Mireille Guyader
Luc Montagnier
Pierre Sonigo
Pierre Tiollais
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Original Assignee
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27251436&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU1225088(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/003,764 external-priority patent/US5051496A/en
Priority claimed from FR8701739A external-priority patent/FR2610632B1/en
Priority claimed from FR8705398A external-priority patent/FR2614025B1/en
Application filed by Institut Pasteur de Lille filed Critical Institut Pasteur de Lille
Publication of AU1225088A publication Critical patent/AU1225088A/en
Application granted granted Critical
Publication of AU608294B2 publication Critical patent/AU608294B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Peptides having immunological properties in common with those of the peptidic skeleton of peptides of viruses of the family HIV-2, particularly the envelope glycoprotein of HIV-2, characterized in that they have also a peptidic structure in common with the peptidic skeleton of peptides of SIV, particularly the envelope glycoprotein of SIV. The invention also relates to diagnosis compositions capable of detecting an infection due to HIV-2 and to vaccine compositions.
AU12250/88A 1987-01-16 1988-01-15 Peptides having immunological properties 2-hiv-2 Expired AU608294B2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US07/003,764 US5051496A (en) 1986-01-22 1987-01-16 Peptides related to human immunodeficiency virus II (HIV-2)
US003764 1987-01-16
FR8701739A FR2610632B1 (en) 1987-02-11 1987-02-11 CHARACTERISTIC PEPTIDES OF HUMAN IMMUNODEFICIENCY RETROVIRUSES (HIV VIRUSES) THEIR APPLICATIONS IN THE DIAGNOSIS OF INFECTIONS DUE TO CERTAIN OF THESE VIRUSES AND, IF NECESSARY, IN VACCINATION AGAINST AIDS
FR8701739 1987-02-11
FR8705398A FR2614025B1 (en) 1987-04-15 1987-04-15 PEPTIDES LIKELY TO BE RECOGNIZED BY ANTIBODIES INDUCED AGAINST HUMAN IMMUNODEFICIENCY RETROVIRUSES (HIV VIRUSES) THEIR APPLICATIONS IN THE DIAGNOSIS OF INFECTIONS DUE TO CERTAIN VIRUSES AND, IF NECESSARY, IN VACCINATION AGAINST AIDS
FR8705398 1987-04-15

Publications (2)

Publication Number Publication Date
AU1225088A true AU1225088A (en) 1988-08-10
AU608294B2 AU608294B2 (en) 1991-03-28

Family

ID=27251436

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12250/88A Expired AU608294B2 (en) 1987-01-16 1988-01-15 Peptides having immunological properties 2-hiv-2

Country Status (9)

Country Link
EP (1) EP0283327B1 (en)
JP (5) JP2948823B2 (en)
AT (1) ATE154808T1 (en)
AU (1) AU608294B2 (en)
DE (1) DE3855947T2 (en)
DK (1) DK174705B1 (en)
ES (1) ES2104556T3 (en)
GR (1) GR3024823T3 (en)
WO (1) WO1988005440A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU617201B2 (en) * 1988-06-13 1991-11-21 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Novel protein and coding sequence for detection and differentiation of siv and hiv-2 group of viruses
AU630861B2 (en) * 1987-11-16 1992-11-12 F. Hoffmann-La Roche Ag Recombinant hiv-2 polypeptides

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701628D0 (en) * 1987-04-16 1987-04-16 Erling Norrby MEANS OF ANALYSIS MM
WO1989002277A2 (en) * 1987-08-28 1989-03-23 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
US5780038A (en) * 1987-11-16 1998-07-14 Roche Diagnostic Systems, Inc. HIV-2 envelope polypeptides
WO1989006276A2 (en) * 1988-01-08 1989-07-13 Dpz Deutsches Primatenzentrum Gesellschaft Mbh Hiv-2-type retroviruses of primates, vaccines, diagnostic and pharmaceutical compositions
JP3093763B2 (en) * 1988-06-09 2000-10-03 インスティチュート・パスツール Precursor antigen of envelope glycoprotein of human retrovirus HIV-2, antigen having immunological homology thereto, method for preparing these antigens and application to diagnosis
FR2632644B1 (en) * 1988-06-10 1994-11-04 Pasteur Institut PRECURSOR ANTIGENS OF HUMAN HIV-2 RETROVIRUS ENVELOPE GLYCOPROTEINS AND ANTIGENS HAVING AN IMMUNOLOGICAL PARENT TO THESE LATTERS. PREPARATION OF THESE ANTIGENS. APPLICATION TO DIAGNOSIS
DE68925660T2 (en) * 1988-06-10 1996-09-26 United Biomedical Inc HIV peptide fragments
FR2635532B1 (en) * 1988-07-29 1992-05-22 Pasteur Institut HYBRID RECOMBINANT HBSAG PARTICLES: MORPHOLOGICAL CHARACTERISTICS OF THE HBSAG ANTIGEN CONTAINING 1 IMMUNOGENIC SEQUENCE INDUCING NEUTRALIZING ANTIBODIES DIRECTED AGAINST HIV OR LIKELY TO BE RECOGNIZED BY SUCH ANTIBODIES; NUCLEOTIDE SEQUENCES ENCODING FOR SUCH PARTICLES; VACCINES CONTAINING THEM
EP0362927A3 (en) * 1988-10-06 1990-11-14 Akzo N.V. Synthetic polypeptides immunochemically reactive with hiv antibodies
CA2003383A1 (en) 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
US5260189A (en) * 1988-12-20 1993-11-09 Immunodiagnostics, Inc. Synthetic HIV-like peptides their compositions and uses
FR2646854A1 (en) * 1989-05-12 1990-11-16 Pasteur Institut Antigens of the envelope transmembrane glycoprotein of a HIV-2 type human retrovirus, antigens exhibiting an immunological relationship with them
SG48125A1 (en) * 1989-05-12 1998-04-17 Pasteur Institut Antigenes of the envelope transmembrance glcoprotein of a human retrovirus of the hiv-2 type and antigens presenting with them an immunological relationship
ES2110283T3 (en) * 1989-05-31 1998-02-01 Pasteur Institut ANTIBODY PROTEINS AND GLYCOPROTEINS OF HIV-2 EHO RETROVIRUSES DIRECTED AGAINST THEM - APPLICATION FOR DIAGNOSIS.
FR2647809B1 (en) * 1989-06-02 1991-09-20 Pasteur Institut OLIGONUCLEOTIDE PRIMERS FOR THE AMPLIFICATION OF THE GENOME OF HIV-1, HIV-2 AND SIV RETROVIRUSES AND THEIR APPLICATIONS TO IN VITRO DIAGNOSIS OF INFECTIONS DUE TO THESE VIRUSES
CA2062829C (en) * 1989-06-02 2007-08-07 Maurice Moncany Nucleotides sequences derived from the genome of type hiv-1, hiv-2 and siv retroviruses, and their applications especially for the amplification the genomes of these retroviruses and for in vitro diagnosis of infections due to these viruses
FR2647810B1 (en) * 1989-06-02 1994-07-22 Pasteur Institut OLIGONUCLEOTIDE PRIMERS FOR THE AMPLIFICATION OF THE GENOME OF HIV-2 AND SIV RETROVIRUSES, AND THEIR APPLICATIONS TO THE IN VITRO DIAGNOSIS OF INFECTIONS DUE TO THESE VIRUSES
US7022814B1 (en) 1992-01-21 2006-04-04 Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2 and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses
DE3934366A1 (en) * 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus VACCINE FOR PROTECTION AGAINST HIV VIRUS INFECTIONS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A DIAGNOSTIC AND IMMUNOTHERAPEUTIC
US6248574B1 (en) * 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
FR2657016B1 (en) * 1990-01-16 1995-08-25 Clonatec Sa PEPTIDES DERIVED FROM THE GLYCOPROTEIN ENVELOPE OF THE HIV-2 VIRUS, THEIR APPLICATIONS FOR THE DETECTION OF AN INFECTION DUE TO THIS VIRUS AND FOR VACCINATION AGAINST AIDS.
ATE164853T1 (en) * 1990-01-16 1998-04-15 Orgenics Ltd PEPTIDES DERIVED FROM VIRUS HIV ENVEL GLYCOPROTEINS, THEIR USE FOR DETECTING INFECTION OF THESE VIRUSES AND FOR VACCINATION AGAINST AIDS
DE4002636A1 (en) * 1990-01-30 1991-08-01 Boehringer Mannheim Gmbh EXPRESSION OF HIV1 AND 2 POLYPEPTIDES AND THEIR USE
AU662534B2 (en) * 1991-06-03 1995-09-07 Syntello Vaccine Development Ab Peptides for use in induction of T cell activation against HIV-1
DE69233630T2 (en) 1991-12-23 2007-05-31 Chiron Corp., Emeryville Sets of HIV probes for use in solution phase sandwich hydride assays
JPH0748276A (en) * 1992-03-26 1995-02-21 Inmeru:Kk Preventing vaccine for hiv infectious disease and production thereof
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
DE4405810A1 (en) 1994-02-23 1995-08-24 Behringwerke Ag Peptides derived from a retrovirus from the HIV group and their use
ES2344926T3 (en) * 1997-08-01 2010-09-09 Bio-Rad Laboratories, Inc. SYNTHETIC ANTIGEN FOR THE DETECTION OF IMMUNOREACTIVE ANTIBODIES WITH HIV VIRUS.
DE19908766C2 (en) * 1999-02-19 2001-02-15 Ulrich Schubert Use of synthetic Vpr peptides of the human immunodeficiency virus type 1 (HIV-1) for the development of therapeutic and diagnostic reagents
WO2005097822A1 (en) * 2004-04-09 2005-10-20 University Of Manitoba Identification of the precise amino acid sequence of the epitope recognized by the potent neutralizing human anti-hiv-1 monoclonal antibody igg1b12
BRPI0514447B8 (en) * 2004-08-17 2021-05-25 Centre Nat Rech Scient use of the immunosuppressive function of a human or simian immunodeficiency virus accessory protein for the preparation of a vaccine
WO2007141650A2 (en) * 2006-01-17 2007-12-13 Instituto De Medicina Molecular Compositions and methods for diagnosing hiv-2 infection

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE250083T1 (en) * 1984-10-18 2003-10-15 Pasteur Institut LAV ANTIGENS AND PEPTIDES
ATE138100T1 (en) * 1984-12-24 1996-06-15 Genentech Inc FUSIONS OF AIDS-RELATED POLYPEPTIDES
NZ215867A (en) * 1985-04-19 1989-10-27 Hoffmann La Roche Aids envelope protein, dna vectors and method of production
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
DE3533440A1 (en) * 1985-09-19 1987-03-26 Hoechst Ag N-SUBSTITUTED 3,4,5,6-TETRAHYDROPHTHALIMIDES, METHODS FOR THEIR PRODUCTION AND THEIR USE IN PLANT PROTECTION
GR862412B (en) * 1985-09-25 1987-01-23 Oncogen Vaccines and immuinoassays for acquired immune deficiency syndrome
FR2593189B1 (en) * 1986-01-22 1989-10-20 Pasteur Institut NEW RETROVIRUS THAT MAY CAUSE AIDS, ANTIGENS OBTAINED FROM THIS RETROVIRUS AND CORRESPONDING ANTIBODIES AND THEIR APPLICATIONS TO AIDS DIAGNOSIS
AR243931A1 (en) * 1986-01-22 1993-09-30 Pasteur Institut Purified antigen, set of reagents for detecting anti-hiv-2 antibodies in a biological fluid that contains these antigens, antibodies, hybridomas and the procedures involved.
EP0269520A3 (en) * 1986-11-21 1988-08-24 Institut Pasteur Retrovirus of the type hiv-2, susceptible to provoke aids, and its antigenic and nucleic-acid constituents
JP3105581B2 (en) * 1991-07-03 2000-11-06 内橋エステック株式会社 Planar temperature fuse
JPH0833969A (en) * 1994-07-22 1996-02-06 Toyota Motor Corp Pressurized casting method

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU630861B2 (en) * 1987-11-16 1992-11-12 F. Hoffmann-La Roche Ag Recombinant hiv-2 polypeptides
AU617201B2 (en) * 1988-06-13 1991-11-21 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Novel protein and coding sequence for detection and differentiation of siv and hiv-2 group of viruses

Also Published As

Publication number Publication date
JPH07300498A (en) 1995-11-14
JP2862810B2 (en) 1999-03-03
GR3024823T3 (en) 1998-01-30
JP2948823B2 (en) 1999-09-13
DK513388D0 (en) 1988-09-15
JP2004002421A (en) 2004-01-08
WO1988005440A1 (en) 1988-07-28
DE3855947T2 (en) 1997-12-11
DK174705B1 (en) 2003-09-29
ES2104556T3 (en) 1997-10-16
JP2002030099A (en) 2002-01-29
JPH01502119A (en) 1989-07-27
AU608294B2 (en) 1991-03-28
EP0283327B1 (en) 1997-06-25
EP0283327A3 (en) 1989-01-04
JPH11322792A (en) 1999-11-24
DE3855947D1 (en) 1997-07-31
EP0283327A2 (en) 1988-09-21
ATE154808T1 (en) 1997-07-15
DK513388A (en) 1988-11-16

Similar Documents

Publication Publication Date Title
AU1225088A (en) Peptides having immunological properties 2-hiv-2
AU3762889A (en) Hiv-3 retrovirus and its use
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
GB2303855B (en) Helicobacter pylori antigenic protein preparation and immunoassays
AU1353295A (en) Peptides derived from a retrovirus of the HIV group, and their use
CA2116764A1 (en) Immunoreactive Hepatitis C Virus Polypeptide Compositions
IL84154A0 (en) Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
WO1989006276A3 (en) Hiv-2-type retroviruses of primates, vaccines, diagnostic and pharmaceutical compositions
DK641787A (en) VIRUS VECTOR CODING A GLYCOPROTEIN FROM THE VIRUS RESPONSIBLE FOR AIDS, VACCINE COVERING THE VIRUS VECTOR OR GLYCOPROTEIN, AND ANTIBODY AGAINST THE GLYCOPROTEIN
EP0306219A3 (en) Novel hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
EP0298633A3 (en) Synthetic polypeptides
CA2065022A1 (en) Rubella peptides
AU2520692A (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus
EP0323157A3 (en) Antiviral compounds and methods
EP0311228A3 (en) Recombinant polypeptides and their uses, including assay for aids virus
AU3929589A (en) Human papilloma virus type 57, the dna thereof and the proteins encoded thereby
AU7514087A (en) Vaccine containing the protein f of the aids virus
DE3571551D1 (en) Vaccines comprising immunogenic protein or peptide complexes
AU8976691A (en) Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof
CA2286399A1 (en) Recombinant proteins of a pakistani strain of hepatitis e and their use in diagnostic methods and vaccines
EP0250128A3 (en) Novel virus isolated from patients with aids
EP0293792A3 (en) Human immunodeficiency virus gag-encoded proteins
HK167295A (en) Precursors of the HIV-2 retrovirus envelope glycoprotein and related antigens
EP0452319A4 (en) Novel protein and coding sequence for detection and differentiation of siv and hiv-2 group of viruses.
EP0288093A3 (en) Strips containing the gp160 envelope protein of the aids virus/hiv, and its use in the detection of the aids antibody